東陽光(600673.SH)決定將所持東陽光藥(01558.HK)內資股全部申請轉為境外上市股份並在聯交所主板上市
格隆匯11月22日丨東陽光(600673.SH)公佈,公司第十屆董事會第十八次會議召開,審議通過了《關於申請公司持有的H股上市公司東陽光藥內資股股份“全流通”的議案》。
2019年11月15日,中國證監會發布了《H股公司境內未上市股份申請“全流通”業務指引》(中國證券監督管理委員會公告[2019]22號),並配套發佈H股“全流通”申請材料目錄及審核關注要點,全面推開H股“全流通”改革。據此,公司決定將所持有的H股上市公司宜昌東陽光長江藥業股份有限公司(股票代碼為01558.HK,“東陽光藥”)內資股股份全部轉換為境外上市股份並在香港聯交所主板上市流通,並委託東陽光藥向中國證監會提出H股“全流通”的申請及辦理其他股份轉換相關事宜,
公司擬將所持有的東陽光藥內資股股份2.262億股全部申請轉為境外上市股份並在香港聯交所主板上市,轉換股份佔東陽光藥總股本的50.40%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.